World Health Organization. (2022). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press.
[2]
Swerdlow, S. H., Campo, E., Harris, N. L., et al. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). IARC, Lyon.
[3]
Eich HT, Diehl V, Görgen H, et al. (2010). Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma. J Clin Oncol. 28(35):5099-5105.
[4]
Ansell SM. (2022). Hodgkin lymphoma: Diagnosis and treatment. Mayo Clin Proc. 97(2):330-344.
[5]
Bröckelmann PJ, Borchmann S, Engert A. (2021). Current and future immunotherapy approaches in Hodgkin lymphoma. Leukemia. 35(7):1849-1864.
[6]
Kumar V, Abbas AK, Aster JC. (2020). Robbins and Cotran Pathologic Basis of Disease (10th edition). Elsevier.
[7]
Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. (2017). Non-Hodgkin lymphoma. Lancet. 390(10091):298-310.
[8]
Glaser SL, Clarke CA, Gomez ED, et al. (2011). Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 117(1):177-188.